284 related articles for article (PubMed ID: 36776894)
1. Metabolic rearrangements and intratumoral heterogeneity for immune response in hepatocellular carcinoma.
Xu FQ; Dong MM; Wang ZF; Cao LD
Front Immunol; 2023; 14():1083069. PubMed ID: 36776894
[TBL] [Abstract][Full Text] [Related]
2. Metabolic reprogramming of immune cells: Shaping the tumor microenvironment in hepatocellular carcinoma.
Xia Y; Brown ZJ; Huang H; Tsung A
Cancer Med; 2021 Sep; 10(18):6374-6383. PubMed ID: 34390203
[TBL] [Abstract][Full Text] [Related]
3. Intratumoral heterogeneity of hepatocellular carcinoma: From single-cell to population-based studies.
Zhang Q; Lou Y; Bai XL; Liang TB
World J Gastroenterol; 2020 Jul; 26(26):3720-3736. PubMed ID: 32774053
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive analysis of the amino acid metabolism-related gene signature for prognosis, tumor immune microenvironment, and candidate drugs in hepatocellular carcinoma.
Li Y; Mo H; Jia S; Wang J; Ma Y; Liu X; Tu K
Front Immunol; 2022; 13():1066773. PubMed ID: 36582227
[TBL] [Abstract][Full Text] [Related]
5. Spatial maps of hepatocellular carcinoma transcriptomes reveal spatial expression patterns in tumor immune microenvironment.
Wang YF; Yuan SX; Jiang H; Li ZX; Yin HZ; Tan J; Dai ZH; Ge CM; Sun SH; Yang F
Theranostics; 2022; 12(9):4163-4180. PubMed ID: 35673582
[No Abstract] [Full Text] [Related]
6. Metabolic Reprogramming of HCC: A New Microenvironment for Immune Responses.
Foglia B; Beltrà M; Sutti S; Cannito S
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108625
[TBL] [Abstract][Full Text] [Related]
7. Aberrant lipid metabolism in hepatocellular carcinoma cells as well as immune microenvironment: A review.
Hu B; Lin JZ; Yang XB; Sang XT
Cell Prolif; 2020 Mar; 53(3):e12772. PubMed ID: 32003505
[TBL] [Abstract][Full Text] [Related]
8. Integrated multiomic analysis reveals comprehensive tumour heterogeneity and novel immunophenotypic classification in hepatocellular carcinomas.
Zhang Q; Lou Y; Yang J; Wang J; Feng J; Zhao Y; Wang L; Huang X; Fu Q; Ye M; Zhang X; Chen Y; Ma C; Ge H; Wang J; Wu J; Wei T; Chen Q; Wu J; Yu C; Xiao Y; Feng X; Guo G; Liang T; Bai X
Gut; 2019 Nov; 68(11):2019-2031. PubMed ID: 31227589
[TBL] [Abstract][Full Text] [Related]
9. Hepatocellular Carcinoma Tumor Microenvironment and Its Implications in Terms of Anti-tumor Immunity: Future Perspectives for New Therapeutics.
Satilmis B; Sahin TT; Cicek E; Akbulut S; Yilmaz S
J Gastrointest Cancer; 2021 Dec; 52(4):1198-1205. PubMed ID: 34625923
[TBL] [Abstract][Full Text] [Related]
10. Deletion of Lactate Dehydrogenase-A Impairs Oncogene-Induced Mouse Hepatocellular Carcinoma Development.
Serra M; Di Matteo M; Serneels J; Pal R; Cafarello ST; Lanza M; Sanchez-Martin C; Evert M; Castegna A; Calvisi DF; Mazzone M; Columbano A
Cell Mol Gastroenterol Hepatol; 2022; 14(3):609-624. PubMed ID: 35714859
[TBL] [Abstract][Full Text] [Related]
11. Heterogeneous immunogenomic features and distinct escape mechanisms in multifocal hepatocellular carcinoma.
Dong LQ; Peng LH; Ma LJ; Liu DB; Zhang S; Luo SZ; Rao JH; Zhu HW; Yang SX; Xi SJ; Chen M; Xie FF; Li FQ; Li WH; Ye C; Lin LY; Wang YJ; Wang XY; Gao DM; Zhou H; Yang HM; Wang J; Zhu SD; Wang XD; Cao Y; Zhou J; Fan J; Wu K; Gao Q
J Hepatol; 2020 May; 72(5):896-908. PubMed ID: 31887370
[TBL] [Abstract][Full Text] [Related]
12. An asparagine metabolism-based classification reveals the metabolic and immune heterogeneity of hepatocellular carcinoma.
Bai J; Tang R; Zhou K; Chang J; Wang H; Zhang Q; Shi J; Sun C
BMC Med Genomics; 2022 Oct; 15(1):222. PubMed ID: 36284275
[TBL] [Abstract][Full Text] [Related]
13. Intratumoural immune heterogeneity as a hallmark of tumour evolution and progression in hepatocellular carcinoma.
Nguyen PHD; Ma S; Phua CZJ; Kaya NA; Lai HLH; Lim CJ; Lim JQ; Wasser M; Lai L; Tam WL; Lim TKH; Wan WK; Loh T; Leow WQ; Pang YH; Chan CY; Lee SY; Cheow PC; Toh HC; Ginhoux F; Iyer S; Kow AWC; Young Dan Y; Chung A; Bonney GK; Goh BKP; Albani S; Chow PKH; Zhai W; Chew V
Nat Commun; 2021 Jan; 12(1):227. PubMed ID: 33431814
[TBL] [Abstract][Full Text] [Related]
14. Reprogramming of central carbon metabolism in hepatocellular carcinoma.
Xia H; Huang Z; Xu Y; Yam JWP; Cui Y
Biomed Pharmacother; 2022 Sep; 153():113485. PubMed ID: 36076503
[TBL] [Abstract][Full Text] [Related]
15. Crosstalk between tumor-associated macrophages and neighboring cells in hepatocellular carcinoma.
Sung PS
Clin Mol Hepatol; 2022 Jul; 28(3):333-350. PubMed ID: 34665953
[TBL] [Abstract][Full Text] [Related]
16. The multiple origin of cancer stem cells in hepatocellular carcinoma.
Anfuso B; El-Khobar KE; Sukowati CH; Tiribelli C
Clin Res Hepatol Gastroenterol; 2015 Sep; 39 Suppl 1():S92-7. PubMed ID: 26186879
[TBL] [Abstract][Full Text] [Related]
17. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
Xing R; Gao J; Cui Q; Wang Q
Front Immunol; 2021; 12():783236. PubMed ID: 34899747
[TBL] [Abstract][Full Text] [Related]
18. Intra-tumoral tertiary lymphoid structures are associated with a low risk of early recurrence of hepatocellular carcinoma.
Calderaro J; Petitprez F; Becht E; Laurent A; Hirsch TZ; Rousseau B; Luciani A; Amaddeo G; Derman J; Charpy C; Zucman-Rossi J; Fridman WH; Sautès-Fridman C
J Hepatol; 2019 Jan; 70(1):58-65. PubMed ID: 30213589
[TBL] [Abstract][Full Text] [Related]
19. Multi-regional sequencing reveals intratumor heterogeneity and positive selection of somatic mtDNA mutations in hepatocellular carcinoma and colorectal cancer.
Li X; Guo X; Li D; Du X; Yin C; Chen C; Fang W; Bian Z; Zhang J; Li B; Yang H; Xing J
Int J Cancer; 2018 Sep; 143(5):1143-1152. PubMed ID: 29569724
[TBL] [Abstract][Full Text] [Related]
20. Fueling HCC Dynamics: Interplay Between Tumor Microenvironment and Tumor Initiating Cells.
Huang H; Tsui YM; Ng IO
Cell Mol Gastroenterol Hepatol; 2023; 15(5):1105-1116. PubMed ID: 36736664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
